Moomoo AI 已提取核心信息
On February 27, 2024, Allarity Therapeutics, Inc. entered into an amendment to their Senior Convertible Notes with 3i, LP. The amendment to the notes, originally dated January 18, 2024, and February 13, 2024, modifies Section 4(c)(vi) to prevent the Holder from converting the notes to common stock if such conversion would require stockholder approval or exceed 19.9% of the common stock shares. All other terms of the Notes remain unchanged. Additionally, on March 1, 2024, Allarity Therapeutics updated their corporate presentation slides and made them available on the company's website. These slides are intended for use in presentations to investors, analysts, and other interested parties. The information provided in the corporate presentation is furnished and not filed, nor is it incorporated by reference into any filing under the Securities Act or the Exchange Act.
On February 27, 2024, Allarity Therapeutics, Inc. entered into an amendment to their Senior Convertible Notes with 3i, LP. The amendment to the notes, originally dated January 18, 2024, and February 13, 2024, modifies Section 4(c)(vi) to prevent the Holder from converting the notes to common stock if such conversion would require stockholder approval or exceed 19.9% of the common stock shares. All other terms of the Notes remain unchanged. Additionally, on March 1, 2024, Allarity Therapeutics updated their corporate presentation slides and made them available on the company's website. These slides are intended for use in presentations to investors, analysts, and other interested parties. The information provided in the corporate presentation is furnished and not filed, nor is it incorporated by reference into any filing under the Securities Act or the Exchange Act.
2024年2月27日，Allarity Therapeutics, Inc.与3i, LP签署了其优先可转换票据的修正案。票据修正案最初于2024年1月18日和2024年2月13日发布，对第4（c）（vi）条进行了修改，以防止持有人将票据转换为普通股，前提是这种转换需要股东批准或超过普通股的19.9％。本票据的所有其他条款保持不变。此外，2024年3月1日，Allarity Therapeutics更新了他们的公司演示幻灯片，并将其发布在公司的网站上。这些幻灯片旨在用于向投资者、分析师和其他有关各方进行演示。公司简报中提供的信息是提供的，不是归档的，也没有以引用方式纳入根据《证券法》或《交易法》提交的任何文件中。
2024年2月27日，Allarity Therapeutics, Inc.与3i, LP签署了其优先可转换票据的修正案。票据修正案最初于2024年1月18日和2024年2月13日发布，对第4（c）（vi）条进行了修改，以防止持有人将票据转换为普通股，前提是这种转换需要股东批准或超过普通股的19.9％。本票据的所有其他条款保持不变。此外，2024年3月1日，Allarity Therapeutics更新了他们的公司演示幻灯片，并将其发布在公司的网站上。这些幻灯片旨在用于向投资者、分析师和其他有关各方进行演示。公司简报中提供的信息是提供的，不是归档的，也没有以引用方式纳入根据《证券法》或《交易法》提交的任何文件中。
有用
没用